Restriction of vancomycin use in a German University Hospital;Erfahrungen mit der beschrankung des einsatzes von vancomycin an einem Deutschen Universitatsklinikum

Medizinische Klinik

Volumn 95, Issue 2, 2000, Pages 69-74

  Glück, Thomas ^a   Linde, Hans Jörg ^b   Wiegrebe, Eckard ^b   Lehn, Norbert ^b   Reng, Michael ^b   Schölmerich, Jürgen ^b  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b NONE

Author keywords

Antibiotic formulary; GISA; MRSA; Vancomycin; VKEC

Indexed keywords

VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL PROTOCOL; DRUG USE; GERMANY; HOSPITAL PHARMACY; PRACTICE GUIDELINE; UNIVERSITY HOSPITAL; COMPARATIVE STUDY; DRUG CONTROL; DRUG UTILIZATION; FOLLOW UP; HUMAN; METHODOLOGY; ORGANIZATION AND MANAGEMENT; PUBLICATION; STATISTICS;

DRUG AND NARCOTIC CONTROL; DRUG UTILIZATION; DRUG UTILIZATION REVIEW; FOLLOW-UP STUDIES; FORMULARIES, HOSPITAL; GERMANY; HOSPITALS, UNIVERSITY; HUMANS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 0034651276     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03044986     Document Type: Article

References (26)

1. Anglim AM, Klym B, Bayers KE, et al. Effect of vancomycin-restriction policy on ordering practices during an outbreak of vancomycin-resistant Enterococcus faecium. Arch Intern Med 1997;157:1132-6.
2. Arthur M, Reynolds PE, Depardieu F, et al. Mechanisms of glycopeptide resistance in enterococci. J Infect 1996;32:11-6.
3. Belliveau PP, Rothmann AL, Maday CE. Limiting vancomycin use to combat vancomycin-resistant Enterococcus faecuim. Am J Health Syst Pharm 1996; 131:1570-5.
4. Dahms RA, Johnson EM, Statz CL, et al. Third generation cephalosporins and Vancomycin as risk factors for postoperative vancomycin-resistant enterococcus infection. Arch Surg 1988;133:1343-6.
5. Evans ME, Kortas KJ. vancomycin use in a university medical center; comparison with hospital infection control practices advisory committee guidelines. Infect Control Hosp Epidemiol 1996;17:356-9.
6. Fekety R. Vancomycin and teicoplanin. In: Mandell GL, Bennett JE, Dolin R. eds. Principles and practice of infectious diseases, 4th edn. New York: Churchill Livingstone, 1995;346-54.
7. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile associated diarrhea and colitis. Am J Gastroenterol 1997;92:739-50.
8. Gerding DN, Johnson S, Peterson LR, et al. Clostridium difficile associated diarrhea and colitis. Infect Control Hosp Epidemiol 1995;16:459-77.
9. Goeckner BJ, Hendershot E, Scott K, et al. A vancomycin monitoring program at a community hospital. Jt Comm J Qual Improv 1998;24:379-85.
10. Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997;40:135-6.
11. Hospital Infection Control Practices Advisory Committee (HICPAC). Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 1995;16:105-13.
12. Kirst HA, Thompson DG, Nicas TL. Historical yearly use of vancomycin. Antimicrob Agents Chemother 1998;42:1303-4.
13. Link H, Blumenstengel K, Böhme A, et al. Antimikrobielle Therapie von unerklärtem Fieber bei Neutropenie. Dtsch Med Wochenschr 1999;124:S3-8.
14. Misan GM, Martin ED, Smith ER, et al. Drug utilization review in a teaching hospital: experience with vancomycin. Eur J Clin Pharmacol 1990;39:457-61.
15. Moreira B, Boyle-Vavra S, deJonge BL, et al. Increased production of penicillin binding protein 2. increased detection of other penicillin-binding proteins, and decreased coagulase activity associated with glycopeptide resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1997;41:1788-93.
16. Noble WC, Virani Z, Cree RG. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992;72:195-8.
17. Quale J, Landman D, Saurina G, et al. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. Clin Inf Dis 1996;23:1020-5.
18. Roghmann MC, Perdue BE, Polish L. Vancomycin use in a hospital with vancomycin restriction. Infect Control Hosp Epidemiol 1999;20:60-3.
19. Shojania KG, Yokoe D, Platt R, et al. Reducing vancomycin use utilizing a computer guideline: results of a randomized controlled trial. J Am Med Inform Assoc 1998;5:554-62.
20. Sieradzki K, Roberts RB, Haber SW, et al. The development of vancomycin resistence in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 1999;340:493-501.
21. Singer MV, Haft R, Barlam, T, et al. Vancomycin control measures at a tertiary care hospital: impact of interventions on volume and pattern of use. Inf Control Hosp Epidemiol 1988;19:248-53.
22. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of resistance in Staphylococcus aureus. N Engl J Med 1999;340:493-501.
23. Uttley AH, Collins CH, Naidoo J, et al. Vancomycin-resistant enterococci. Lancet 1988;1:57-8.
24. Van der Auwera P, Pensart N, Korten V, et al. Influence of oral glycopeptides on the fecal flora of human volunteers: selection of highly glycopeptide-resistant enterococci. J Infect Dis 1996;173:1129-36.
25. Witte W, Klare I, Glycopeptide resistant Enterococcus faecium outside hospitals. A commentary. Microb Drug Res 1995;1:259.
26. Woodford N, Johnson AP, Morrison D, et al. Current perspectives on glycopeptide resistance. Clin Microbiol Rev 1995;8:585-615.